Clinicians need critical diagnostics earlier to empower the best, actionable care pathways.
Empowered clinicians give millions the opportunity of timely treatment and improved patient outcomes.
Is to bring trusted diagnostics to the point of initial patient interaction, to expand access of quality healthcare to new settings, no matter where that patient interaction occurs
Timely Host Response Diagnostics for SEPSIS and Pneumonia
*The Nanōmix eLab® S1 Panel for Critical Infection has received CE Mark; other assays in development and regulatory review.
Nanōmix has announced that it has entered into a distribution agreement with Gepa Srl (“Gepa”), a distributor and supplier of diagnostic products in Italy.
Nanōmix has entered into an exclusive distribution agreement with Woodley Equipment Company, Ltd. (“Woodley”), a global veterinary distributor.
Nanōmix has entered into a multi-region distribution agreement with Mast Group Limited (“Mast”), an independent world class manufacturer and supplier of diagnostic products for clinical, industrial and veterinary testing.
Nanōmix Corporation announced a new distribution agreement with Diaclinic SpA, a medical distributor headquartered in Santiago, Chile. Diaclinic will market and distribute the Nanōmix eLab in the Republic of Chile.
IPS will market and distribute the Nanōmix eLab® system, including the Nanōmix S1 Panel assay and future, new test products for the eLab system, in multiple countries throughout the Middle East.
Point-of-care technology to offer patients a timely, highly accurate status of their protection against COVID-19.
